Application error: a client-side exception has occurred (see the browser console for more information).

Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate ... fruquintinib), a selective oral inhibitor of vascular endothelial growth ...